MEDFORD, N.Y., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in the development, manufacture and marketing of point-of-care diagnostic tests (“POCT”) for infectious diseases, announced today that the company received its first purchase order for its DPP® HIV-Syphilis Assay from its distributor in Mexico . The DPP® HIV-Syphilis Assay is based on the company’s patented Dual Path Platform (DPP®), a POCT platform that is well suited for multiplexing, and that in this case adds a syphilis biomarker to the company’s already FDA-approved DPP® HIV 1/2 test. The addition of this marker has resulted in a unique finger-stick whole blood test that can help reduce the transmission of both HIV and syphilis from mother to child. Globally, more pregnant women are infected with syphilis than HIV, and pre-natal testing is an essential tool to help prevent transmission of both diseases to the unborn child.
Help employers find you! Check out all the jobs and post your resume.
